New CAR-T therapy targets Hard-to-Treat multiple myeloma in early trial
NCT ID NCT07139509
First seen Jan 11, 2026 · Last updated May 17, 2026 · Updated 18 times
Summary
This early-stage study tests a new treatment for adults with multiple myeloma that has returned or stopped responding to standard therapies. The treatment uses specially engineered immune cells from donated umbilical cord blood to attack cancer cells. The main goals are to check safety, find the best dose, and see how well it works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA(MM) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xi'an No.3 Hospital
RECRUITINGXi’an, Shanxi, 710016, China
Conditions
Explore the condition pages connected to this study.